Translation of "paediatric use " (English → French) :

paediatric use marketing authorisation | PUMA [Abbr.]

medicinal product for use in the paediatric population | paediatric drug | paediatric medicinal product | paediatric medicine

Asian Pan-Pacific Society of Paediatric Gastroenterology and Nutrition [ APPSGAN | Asian Pan-Pacific Association of Gastroenterology and Nutrition | Asian-Pacific Association of Gastroenterology | Asian Pacific Paediatric Gastro-enterology Group | Asian Pacific Society for Paediatric Gastroenterology ]

Canadian Association of Paediatric Health Centres [ CAPHC | Canadian Association of Paediatric Hospitals ]

Association for European Paediatric Cardiology [ AEPC | Association of European Paediatric Cardiologists ]

carry out paediatric surgery | carry out pediatric surgery | perform paediatric surgery | perform pediatric surgery

mental care of infants, children and adolescents | personality study of infants, children and adolescents | paediatric mental treatment | paediatric psychology

blood collection procedures for children and young adults | paediatric phlebotomy procedure | paediatric phlebotomy procedures | pediatric phlebotomy procedures

Definition: This block contains a wide variety of disorders that differ in severity and clinical form but that are all attributable to the use of one or more psychoactive substances, which may or may not have been medically prescribed. The third character of the code identifies the substance involved, and the fourth character specifies the clinical state. The codes should be used, as required, for each substance specified, but it should be noted that not all fourth character codes are applicable to all substances. Identification of the psychoactive substance should be based on as many sources of information as possible. These include sel ...[+++]f-report data, analysis of blood and other body fluids, characteristic physical and psychological symptoms, clinical signs and behaviour, and other evidence such as a drug being in the patient's possession or reports from informed third parties. Many drug users take more than one type of psychoactive substance. The main diagnosis should be classified, whenever possible, according to the substance or class of substances that has caused or contributed most to the presenting clinical syndrome. Other diagnoses should be coded when other psychoactive substances have been taken in intoxicating amounts (common fourth character .0) or to the extent of causing harm (common fourth character .1), dependence (common fourth character .2) or other disorders (common fourth character .3-.9). Only in cases in which patterns of psychoactive substance-taking are chaotic and indiscriminate, or in which the contributions of different psychoactive substances are inextricably mixed, should the diagnosis of disorders resulting from multiple drug use (F19.-) be used. | Modifiers The following fourth-character subdivisions are for use with categories F10-F19: Code Title .0 Acute intoxication A condition that follows the administration of a psychoactive substance resulting in disturbances in level of consciousness, cognition, perception, affect or behaviour, o ...

This Regulation aims to facilitate the development and accessibility of medicinal products for use in the paediatric population, to ensure that medicinal products used to treat the paediatric population are subject to ethical research of high quality and are appropriately authorised for use in the paediatric population, and to improve the information available on the use of medicinal products in the various paediatric populations.

In order to increase the availability of information on the use of medicinal products in the paediatric population, and to avoid unnecessary repetition of studies in the paediatric population which do not add to the collective knowledge, the European database provided for in Article 11 of Directive 2001/20/EC should include a European register of clinical trials of medicinal products for paediatric use comprising all ongoing, prematurely terminated, and completed paediatric studies conducted both in the Community and in third countries.

Public health threats from the use of untested medicinal products in the paediatric population can be safely addressed through the study of medicinal products for the paediatric population, which should be carefully controlled and monitored through the specific requirements for the protection of the paediatric population who take part in clinical trials in the Community laid down in Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clin ...[+++]ical trials on medicinal products for human use

The committee therefore recommends that the Minister of Health direct Health Canada to explore ways to provide focussed and thorough monitoring of the off-label use of prescription drugs among children and youth less than 18 years of age, particularly the use of antipsychotics and antidepressants, including further collaboration with the Canadian Paediatric Society to enhance the Canadian Paediatric Surveillance Program.